A 61-year-old female presented with progressive erythema on her foot ([Picture A](#g001){ref-type="fig"}). She had previously undergone surgical resection of a pancreatic neuroendocrine tumor with a Ki-67 index of 15%, octreotide treatment, chemotherapy, and transarterial embolization over the previous eight years. Metastases to the liver were identified on magnetic resonance imaging ([Picture B](#g001){ref-type="fig"}). We initially administered sunitinib (37.5 mg per day) in an effort to inhibit the vascular endothelial growth factor- and platelet-derived growth factor-mediated receptor signaling ([@B1]). Four months later, the erythema was resolved ([Picture C](#g001){ref-type="fig"}). Magnetic resonance imaging revealed that the liver metastases responded to this treatment ([Picture D](#g001){ref-type="fig"}). The serum glucagon level (initially 803 pg/mL; reference level 71-174 pg/mL) fell to 425 pg/mL. We thought that the successful treatment of glucagonoma by sunitinib improved the necrolytic migratory erythema. Because necrolytic migratory erythema is an important paraneoplastic syndrome associated with glucagonoma ([@B2]), physicians should be aware of this symptom.

![](1349-7235-57-2283-g001){#g001}

**The authors state that they have no Conflict of Interest (COI).**

[^1]: Correspondence to Dr.　Nagio Takigawa, <ntakigaw@gmail.com>
